Sugi Predict

Sugi Predict / Compounds / Phenyl Cinnamate

Phenyl Cinnamate

Phenyl Cinnamate

SCHEMBL1055161

O=C(C=Cc1ccccc1)Oc1ccccc1

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.77
▸ HTR1A P08908 1/20 0.61
▸ LMNA P02545 4/20 0.59
▸ MAPT P10636 3/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ HDAC3 O15379 2/20 0.59
▸ HDAC4 P56524 2/20 0.59
▸ HDAC1 Q13547 2/20 0.59
▸ HDAC2 Q92769 2/20 0.59
▸ HDAC8 Q9BY41 2/20 0.59
▸ HDAC6 Q9UBN7 2/20 0.59
▸ PLIN1 O60240 2/20 0.59
▸ RECQL P46063 2/20 0.59
▸ PLIN5 Q00G26 2/20 0.59
▸ ABHD5 Q8WTS1 2/20 0.59
▸ TNKS O95271 1/20 0.59
▸ HCAR2 Q8TDS4 1/20 0.59
▸ HDAC7 Q8WUI4 1/20 0.59
▸ HDAC10 Q969S8 1/20 0.59
▸ HDAC11 Q96DB2 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenyl Cinnamate SCHEMBL1055160 1.00 KMT2A (0.77) KMT2AHTR1ALMNAMAPTSMN1; SMN2
SCHEMBL16982630 0.96 KMT2A (0.83) KMT2AHTR1ALMNAMAPTSMN1; SMN2
Phenyl Cinnamate SCHEMBL27584041 0.93 KMT2A (0.68) KMT2AHTR1ALMNAMAPTSMN1; SMN2
SCHEMBL13978652 0.90 KMT2A (0.69) KMT2AHTR1ALMNAMAPTSMN1; SMN2
SCHEMBL17802341 0.89 KMT2A (0.68) KMT2AHTR1ALMNAHDAC2ALDH1A1
SCHEMBL14634510 0.89 KMT2A (0.68) KMT2AHTR1AMAPTHCAR2CYP2D6
SCHEMBL14634502 0.89 KMT2A (0.73) KMT2AHTR1ALMNAMAPTSMN1; SMN2
SCHEMBL31453510 0.89 KMT2A (0.73) KMT2AHTR1ALMNAMAPTSMN1; SMN2
SCHEMBL14634511 0.89 KMT2A (0.68) KMT2AHTR1AMAPTHCAR2CYP2D6
SCHEMBL15908399 0.89 KMT2A (0.68) KMT2AHTR1ALMNAHDAC2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122011640-A Intermediate film for dimming glass and application thereof 浙江精一新材料科技有限公司 2026-05-12 — — CN claimed
CN-116023202-A Synthetic method of alpha-chlorarone derivative 西南大学 2023-04-28 — — CN claimed
US-20220234987-A1 STYRYL CARBOXYLATE DERIVATIVES Renovel Innovations, Inc. 2022-07-28 — — US claimed
CN-109004051-A A kind of solar battery back film 苏州中来光伏新材股份有限公司 2018-12-14 — — CN claimed
EP-3149135-A2 PERFUME COMPOSITIONS Givaudan S.A. (CH) 2017-04-05 — — EP claimed
US-20170073614-A1 Perfume Compositions GIVAUDAN SA (CH) 2017-03-16 — — US claimed
WO-2015181257-A2 PERFUME COMPOSITIONS GIVAUDAN SA (CH) 2015-12-03 — — WO claimed
US-20100234467-A1 METHODS FOR IMPROVING BIOAVAILABILITY OF A RENIN INHIBITOR OTTINGER ISABEL 2010-09-16 — — US claimed
US-20100034766-A1 Malodor Counteracting Compositions GIVAUDAN SA (CH) 2010-02-11 — — US claimed
US-20100021413-A1 Malodor Counteracting Compositions GIVAUDAN SA (CH) 2010-01-28 — — US claimed
EP-2086594-A1 MALODOR COUNTERACTING COMPOSITIONS Givaudan SA (CH) 2009-08-12 — — EP claimed
EP-2079487-A1 MALODOR COUNTERACTING COMPOSITIONS Givaudan SA (CH) 2009-07-22 — — EP claimed
CN-101356173-A Novel pyridopyrazines and their use as modulators of kinases AETERNA ZENTARIS GMBH (DE) 2009-01-28 — — CN claimed
EP-1927350-A1 Methods for improving bioavailability of a renin inhibitor Novartis AG (CH) 2008-06-04 — — EP claimed
WO-2008062066-A1 METHODS FOR IMPROVING BIOAVAILABILITY OF A RENIN INHIBITOR NOVARTIS AG (CH) 2008-05-29 — — WO claimed
WO-2008055372-A1 MALODOR COUNTERACTING COMPOSITIONS GIVAUDAN SA (CH) 2008-05-15 — — WO claimed
WO-2008049257-A1 MALODOR COUNTERACTING COMPOSITIONS GIVAUDAN SA (CH) 2008-05-02 — — WO claimed
US-20070149484-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES ZENTARIS GMBH (DE) 2007-06-28 — — US claimed
EP-0430023-A1 Process for the preparation of substituted phenylcinnamates BASF Corporation (US) 1991-06-05 — — EP claimed
EP-0320954-A2 Transparent resin and transparent resin products NIPPON OIL AND FATS COMPANY, LIMITED (JP) 1989-06-21 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100034766-A1 Malodor Counteracting Compositions MTNR1A, MTNR1B, MC4R KMT2A 3591/4885HTR1A 1102/4885LMNA 4312/4885
US-20070149484-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES MAP4K2, MAP3K15, MAP3K5 KMT2A 1329/4885HTR1A 1754/4885LMNA 2535/4885
US-20220234987-A1 STYRYL CARBOXYLATE DERIVATIVES ACACB, ACACA, FABP7 KMT2A 1056/4885HTR1A 2749/4885LMNA 4061/4885
US-20100234467-A1 METHODS FOR IMPROVING BIOAVAILABILITY OF A RENIN INHIBITOR REN, ACE, AGTR1 KMT2A 3919/4885HTR1A 1183/4885LMNA 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.